Dianthus Therapeutics (DNTH) to Announce Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Dianthus Therapeutics to announce earnings of ($0.93) per share and revenue of $0.2970 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, analysts expect Dianthus Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $104.09 on Thursday. Dianthus Therapeutics has a one year low of $18.08 and a one year high of $107.99. The stock has a fifty day moving average price of $91.76 and a 200 day moving average price of $77.61. The stock has a market cap of $5.69 billion, a P/E ratio of -25.20 and a beta of 1.20.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on DNTH shares. Wedbush increased their price objective on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $117.82.

Insiders Place Their Bets

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 87,779 shares of company stock worth $7,985,235 over the last three months. 3.02% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its stake in Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after buying an additional 2,503,311 shares during the last quarter. Vestal Point Capital LP raised its stake in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. State Street Corp raised its stake in shares of Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock valued at $62,129,000 after acquiring an additional 836,571 shares during the last quarter. Polar Capital Holdings Plc acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $29,434,000. Finally, Marshall Wace LLP acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $22,545,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.